Claudio Chuaqui - BiogenIdec | 人才画像

基本信息

Career Trajectory

Bio

Claudio Chuaqui currently works at Syros Pharmaceuticals, Inc.. Claudio does research in Cancer Research and Medicinal Chemistry. Their most recent publication is 'Discovery and Optimization of a Novel Series of Highly Selective JAK1 Kinase Inhibitors'.

Research Interests

Papers共 98 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

Discovery of CC-99677, a selective targeted covalent MAPKAPK2 (MK2) inhibitor for autoimmune disorders

John Malona,Claudio Chuaqui, Boris M Seletsky,Lisa Beebe,Susan Cantin, Daniel VAN Kalken,Kelly Fahnoe,Zhigang Wang, Beth Browning, Hilary Szabo, Louise A Koopman,Tamas Oravecz,Joseph J McDonald,Francisco Ramirez-Valle,Rajula Gaur,Kofi A Mensah,Michael Thomas,Jamie N Connarn, Haiqing Hu, Matthew D Alexander,Alan F Corin

Translational Research（2022）

Cited7Views0WOSBibtex

Combination of CDK12 Inhibition and Olaparib Enhances Genomic Instability in Cancer Models

S. Alnemy, N. Rajagopal, P. Perera, R. Shawgo, W. Dworakowski, D. LaPlaca,J. Carulli,C. Chuaqui, S. Hu, D. Moebius

European journal of cancer（2022）

Cited0Views0Bibtex

Abstract 5393: an Oral and Selective CDK12 Inhibitor Demonstrates Robust Anti-Tumor Activity

Shan hu, David Moebius,Wojciech Dworakowski,Elliott Cooper, Derek LaPlaca,Sydney Alnemy,Phone Perera,Jason Marineau,Claudio Chuaqui,John P. Carulli,Eric N. Olson

Cancer researchno. 12_Supplement (2022): 5393-5393

Cited0Views0Bibtex

CDK11 is a Selective Dependency in Neuroblastoma Harboring Loss of Chromosome 1P36

M. Guenther,Y. Wei, S. Stein,A. D'Ippolito, D. Farouq, D. Moebius,J. Marineau, E. Cooper,C. Chuaqui,J. Carulli, E. Olson

European journal of cancer（2022）

Cited0Views0Bibtex

Discovery of SY-5609: A Selective, Noncovalent Inhibitor of CDK7

Jason J. Marineau,Kristin B. Hamman,Shanhu Hu,Sydney Alnemy, Janessa Mihalich,Anzhelika Kabro, Kenneth Matthew Whitmore,Dana K. Winter,Stephanie Roy,Stephane Ciblat,Nan Ke,Anneli Savinainen,Ashraf Wilsily,Goran Malojcic,Robert Zahler,Darby Schmidt,Michael J. Bradley,Nigel J. Waters,Claudio Chuaqui

Journal of medicinal chemistry（2021）

Cited20Views0WOSBibtex

SY-5609, an orally available selective CDK7 inhibitor demonstrates broad anti-tumor activity in vivo

Shanhu Hu,Jason Marineau,Kristin Hamman,Michael Bradley,Anneli Savinainen,Sydney Alnemy,Nisha Rajagopal,David Orlando,Claudio Chuaqui,Eric Olson

Cancer Research（2019）

Cited12Views0Bibtex

A Novel MK2 Inhibitor for the Treatment of Ankylosing Spondylitis and Other Inflammatory Diseases

Francisco Ramirez-Valle,Mary Adams,Lisa Beebe,Jian Chen,Claudio Chuaqui,Jamie Connarn,Alan Corin, Karen Dingley,J. Michael Ellis,Rajula Gaur,Lawrence Hamann,John Malona,Kofi Mensah,Maria Palmisano

ARTHRITIS & RHEUMATOLOGY（2019）

Cited1Views0Bibtex

An oral and selective CDK7 inhibitor demonstrates substantial anti-tumor effect in breast and ovarian cancer models

S. Hu,J. Marineau, M. Bradley, K. Hamman,S. Alnemy,D. Smith,J. Carulli,C. Chuaqui

EUROPEAN JOURNAL OF CANCER（2018）

Cited0Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn